Skip to Content
Søg Menu

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

Clinical and biological markers associated with long-term survival for patients with acute myeloid leukemia in remission after chemotherapy in the QUAZAR AML-001 trial of oral AZACITIDINE.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
ASH23AML Play the Video 03:32

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ BestPractice Nordic
ASH23AML
Sergio Giralt

In the Era of Personalized Treatment and Targeted Therapies

/ Sergio Giralt
ASH23AML Play the Video 2:46

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

/ BestPractice Nordic
EHA23AML

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

/ Mark Levis
EHA23AML Play the Video 05:06

EHA23 – Novel CAR Therapy for AML Shows Favorable Pre-Clinical Outcomes

/ BestPractice Nordic
CAR-TEHA23AML

The Link Between Breast Cancer and Hematologic Cancers

/ Cathrine Fonnesbech Hjorth
BrystcancerLeukæmiAML

An Update on New Treatments for Acute Myeloid Leukemia

/ Hans Beier Ommen
BehandlingAML

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top